Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China
Jinlong Huang, Hanyun Ye, Jingyang Lin, Dan Luo, Ping Huang, Xiaochun Zheng · 2026
Read Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China by Jinlong Huang, Hanyun Ye, Jingyang Lin, Dan Luo, Ping Huang, Xiaochun Zheng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351853.txt.
Description
Jinlong Huang and colleagues priced a second-line treatment for pancreatic cancer in China. The regimen adds liposomal irinotecan to standard chemotherapy. The comparison was the same chemotherapy with a placebo. Pancreatic cancer leaves patients few options, and this drug is costly. The team built a lifetime cost model from the trial behind the regimen. It counted costs and quality-adjusted years of life.
The drug bought a small slice of healthy time, about one quality-adjusted month. Its cost per unit of gain sat far beyond China's usual limit. No fair change in the inputs rescued the result. Only a price cut of nearly ninety percent would make it good value. The study hands negotiators a hard number to argue from.
Catalog record
| CREATOR | Jinlong Huang, Hanyun Ye, Jingyang Lin, Dan Luo, Ping Huang, Xiaochun Zheng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28764 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |